Literature DB >> 33077938

Restoration of visual function in adult mice with an inherited retinal disease via adenine base editing.

Susie Suh1,2, Elliot H Choi3,4, Henri Leinonen3, Andrzej T Foik5,6, Gregory A Newby7,8,9, Wei-Hsi Yeh7,8,9,10, Zhiqian Dong3, Philip D Kiser11,12, David C Lyon5, David R Liu7,8,9, Krzysztof Palczewski13,14,15.   

Abstract

Cytosine base editors and adenine base editors (ABEs) can correct point mutations predictably and independent of Cas9-induced double-stranded DNA breaks (which causes substantial indel formation) and homology-directed repair (which typically leads to low editing efficiency). Here, we show, in adult mice, that a subretinal injection of a lentivirus expressing an ABE and a single-guide RNA targeting a de novo nonsense mutation in the Rpe65 gene corrects the pathogenic mutation with up to 29% efficiency and with minimal formation of indel and off-target mutations, despite the absence of the canonical NGG sequence as a protospacer-adjacent motif. The ABE-treated mice displayed restored RPE65 expression and retinoid isomerase activity, and near-normal levels of retinal and visual functions. Our findings motivate the further testing of ABEs for the treatment of inherited retinal diseases and for the correction of pathological mutations with non-canonical protospacer-adjacent motifs.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33077938      PMCID: PMC7885272          DOI: 10.1038/s41551-020-00632-6

Source DB:  PubMed          Journal:  Nat Biomed Eng        ISSN: 2157-846X            Impact factor:   25.671


  54 in total

1.  Improvement and decline in vision with gene therapy in childhood blindness.

Authors:  Samuel G Jacobson; Artur V Cideciyan; Alejandro J Roman; Alexander Sumaroka; Sharon B Schwartz; Elise Heon; William W Hauswirth
Journal:  N Engl J Med       Date:  2015-05-03       Impact factor: 91.245

Review 2.  Genome editing. The new frontier of genome engineering with CRISPR-Cas9.

Authors:  Jennifer A Doudna; Emmanuelle Charpentier
Journal:  Science       Date:  2014-11-28       Impact factor: 47.728

Review 3.  Development and applications of CRISPR-Cas9 for genome engineering.

Authors:  Patrick D Hsu; Eric S Lander; Feng Zhang
Journal:  Cell       Date:  2014-06-05       Impact factor: 41.582

4.  Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials.

Authors:  Albert M Maguire; Stephen Russell; Jennifer A Wellman; Daniel C Chung; Zi-Fan Yu; Amy Tillman; Janet Wittes; Julie Pappas; Okan Elci; Kathleen A Marshall; Sarah McCague; Hannah Reichert; Maria Davis; Francesca Simonelli; Bart P Leroy; J Fraser Wright; Katherine A High; Jean Bennett
Journal:  Ophthalmology       Date:  2019-06-22       Impact factor: 12.079

5.  Long-Term Structural Outcomes of Late-Stage RPE65 Gene Therapy.

Authors:  Kristin L Gardiner; Artur V Cideciyan; Malgorzata Swider; Valérie L Dufour; Alexander Sumaroka; András M Komáromy; William W Hauswirth; Simone Iwabe; Samuel G Jacobson; William A Beltran; Gustavo D Aguirre
Journal:  Mol Ther       Date:  2019-09-03       Impact factor: 11.454

Review 6.  Molecular genetics of Leber congenital amaurosis.

Authors:  Frans P M Cremers; José A J M van den Hurk; Anneke I den Hollander
Journal:  Hum Mol Genet       Date:  2002-05-15       Impact factor: 6.150

7.  Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement.

Authors:  Artur V Cideciyan; Samuel G Jacobson; William A Beltran; Alexander Sumaroka; Malgorzata Swider; Simone Iwabe; Alejandro J Roman; Melani B Olivares; Sharon B Schwartz; András M Komáromy; William W Hauswirth; Gustavo D Aguirre
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-22       Impact factor: 11.205

Review 8.  Leber congenital amaurosis: genes, proteins and disease mechanisms.

Authors:  Anneke I den Hollander; Ronald Roepman; Robert K Koenekoop; Frans P M Cremers
Journal:  Prog Retin Eye Res       Date:  2008-06-01       Impact factor: 21.198

Review 9.  Gene therapy for RPE65-related retinal disease.

Authors:  Virginia Miraldi Utz; Razek Georges Coussa; Fares Antaki; Elias I Traboulsi
Journal:  Ophthalmic Genet       Date:  2018-10-18       Impact factor: 1.803

10.  Long-term effect of gene therapy on Leber's congenital amaurosis.

Authors:  James W B Bainbridge; Manjit S Mehat; Venki Sundaram; Scott J Robbie; Susie E Barker; Caterina Ripamonti; Anastasios Georgiadis; Freya M Mowat; Stuart G Beattie; Peter J Gardner; Kecia L Feathers; Vy A Luong; Suzanne Yzer; Kamaljit Balaggan; Ananth Viswanathan; Thomy J L de Ravel; Ingele Casteels; Graham E Holder; Nick Tyler; Fred W Fitzke; Richard G Weleber; Marko Nardini; Anthony T Moore; Debra A Thompson; Simon M Petersen-Jones; Michel Michaelides; L Ingeborgh van den Born; Andrew Stockman; Alexander J Smith; Gary Rubin; Robin R Ali
Journal:  N Engl J Med       Date:  2015-05-04       Impact factor: 91.245

View more
  26 in total

1.  Adenine Base Editing In Vivo with a Single Adeno-Associated Virus Vector.

Authors:  Han Zhang; Nathan Bamidele; Pengpeng Liu; Ogooluwa Ojelabi; Xin D Gao; Tomás Rodriguez; Haoyang Cheng; Karen Kelly; Jonathan K Watts; Jun Xie; Guangping Gao; Scot A Wolfe; Wen Xue; Erik J Sontheimer
Journal:  GEN Biotechnol       Date:  2022-06-14

Review 2.  Therapeutic in vivo delivery of gene editing agents.

Authors:  Aditya Raguram; Samagya Banskota; David R Liu
Journal:  Cell       Date:  2022-07-06       Impact factor: 66.850

3.  Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases.

Authors:  Hyewon Jang; Dong Hyun Jo; Chang Sik Cho; Jeong Hong Shin; Jung Hwa Seo; Goosang Yu; Ramu Gopalappa; Daesik Kim; Sung-Rae Cho; Jeong Hun Kim; Hyongbum Henry Kim
Journal:  Nat Biomed Eng       Date:  2021-08-26       Impact factor: 29.234

4.  Translational enhancement by base editing of the Kozak sequence rescues haploinsufficiency.

Authors:  Chiara Ambrosini; Eliana Destefanis; Eyemen Kheir; Francesca Broso; Federica Alessandrini; Sara Longhi; Nicolò Battisti; Isabella Pesce; Erik Dassi; Gianluca Petris; Anna Cereseto; Alessandro Quattrone
Journal:  Nucleic Acids Res       Date:  2022-10-14       Impact factor: 19.160

5.  Precision genome editing in the eye.

Authors:  Susie Suh; Elliot H Choi; Aditya Raguram; David R Liu; Krzysztof Palczewski
Journal:  Proc Natl Acad Sci U S A       Date:  2022-09-19       Impact factor: 12.779

Review 6.  From Bench to Bed: The Current Genome Editing Therapies for Glaucoma.

Authors:  Meihui He; Rong Rong; Dan Ji; Xiaobo Xia
Journal:  Front Cell Dev Biol       Date:  2022-05-16

Review 7.  New Editing Tools for Gene Therapy in Inherited Retinal Dystrophies.

Authors:  Juliette Pulman; José-Alain Sahel; Deniz Dalkara
Journal:  CRISPR J       Date:  2022-05-03

8.  CRISPR correction of the Finnish ornithine delta-aminotransferase mutation restores metabolic homeostasis in iPSC from patients with gyrate atrophy.

Authors:  Rocio Maldonado; Sami Jalil; Timo Keskinen; Anni I Nieminen; Mervi E Hyvönen; Risto Lapatto; Kirmo Wartiovaara
Journal:  Mol Genet Metab Rep       Date:  2022-04-01

Review 9.  In vivo somatic cell base editing and prime editing.

Authors:  Gregory A Newby; David R Liu
Journal:  Mol Ther       Date:  2021-09-10       Impact factor: 11.454

10.  Imperfect guide-RNA (igRNA) enables CRISPR single-base editing with ABE and CBE.

Authors:  Dongdong Zhao; Guo Jiang; Ju Li; Xuxu Chen; Siwei Li; Jie Wang; Zuping Zhou; Shiming Pu; Zhubo Dai; Yanhe Ma; Changhao Bi; Xueli Zhang
Journal:  Nucleic Acids Res       Date:  2022-04-22       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.